Lemaitre Vasculr SEC Filings

LeMaitre Vascular Inc reported that a company director received new equity awards in the form of common stock and stock options. On 12/10/2025, the director acquired 533 shares of common stock through a restricted stock unit award at a price of $0 per share, bringing direct beneficial ownership to 62,340 shares.

The disclosure also shows stock options covering 3,431 shares of common stock with an exercise price of $83.66 and an expiration date of 12/10/2030. The restricted stock units vest 33 1/3% on 12/1/2026, with the remainder vesting in equal annual installments over the next two years, while the options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the following two years.

LeMaitre Vascular reported that one of its directors received new equity awards. On 12/10/2025 the director was granted 533 restricted stock units of common stock at a price of $0 and 3,431 stock options with an exercise price of $83.66 per share.

The restricted stock units vest 33 1/3% on 12/1/2026, with the rest vesting in equal annual installments over the following two years. The options vest over three years at 33 1/3% on the first anniversary of 12/01/2025, with the balance vesting in equal annual installments over the remaining two years, and expire on 12/10/2030. After this grant, the director beneficially owns 3,455 common shares directly, 181 shares indirectly through a spouse, and 3,431 options.

LeMaitre Vascular reported insider equity transactions by its Senior Vice President, Operations on a Form 4. On 12/06/2025, 2 shares of common stock were acquired at $0 per share upon the release of dividend equivalent rights, bringing direct holdings before tax withholding to 3,712 shares. Also on that date, 69 shares were disposed of at $84.53 per share as shares withheld by the issuer to satisfy tax withholding obligations from previously awarded restricted stock units, resulting in 3,643 common shares owned directly.

The report also shows several acquisitions of dividend equivalent rights on 12/04/2025 that accrued on restricted stock unit and performance share unit awards originally granted on 12/11/2021, 12/12/2022, 12/8/2023, and 12/6/2024. Each dividend equivalent right is stated to be the economic equivalent of one share of LeMaitre Vascular common stock and to vest proportionately with the related awards.

LeMaitre Vascular, Inc. (LMAT) reported an insider equity transaction by a director. On 11/21/2025, the reporting person exercised a stock option to buy 7,500 shares of common stock at an exercise price of $37.29 per share, as shown in Table II. These shares, reported in Table I, were acquired and increased the director’s directly owned common stock holdings to 64,801 shares following the transaction. The option, originally granted on 12/02/2020 and fully vested and exercisable, was due to expire on 12/02/2025 and shows 0 derivative securities remaining from this grant after the exercise.

LeMaitre Vascular, Inc. (LMAT) Chairman and CEO, who is also a director, reported an insider transaction on 11/20/2025. He exercised a stock option to buy 2,681 shares of common stock at an exercise price of $41.02 per share, converting a derivative position into directly owned stock. After this exercise, he directly beneficially owns 1,665,984 shares of LeMaitre Vascular common stock.

In addition, 21,300 shares are held indirectly through the “LeMaitre Irrevocable Life Insurance Trust of 2025” for the benefit of his child or children. He disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest. The option that was exercised covered 2,681 shares, was fully vested and exercisable, and now shows 0 derivative securities remaining from that grant.

LeMaitre Vascular (LMAT) reported Q3 2025 results showing higher sales and earnings. Net sales were $61,046 thousand, up from $54,819 thousand a year ago. Net income rose to $17,362 thousand, and diluted EPS was $0.75 versus $0.49. Gross profit increased to $45,955 thousand as cost of sales declined to $15,091 thousand.

Results included a one‑time Employee Retention Credit benefit recorded in Q3: $4.8 million recognized as reductions to cost of sales ($2.7 million), sales and marketing ($0.8 million), general and administrative ($0.3 million), and research and development ($0.3 million), plus $0.7 million of interest income, and $0.7 million of related professional fees in general and administrative expense. The company did not recognize credits for claims filed for July–September 2021 under the One Big Beautiful Bill Act.

Year‑to‑date operating cash flow was $58,094 thousand. The balance sheet showed cash and cash equivalents of $25,494 thousand and short‑term marketable securities of $317,561 thousand. Convertible senior notes outstanding totaled $172,500 thousand; the conversion rate was adjusted to 8.3637 per $1,000 after a $0.20 per‑share dividend, which continued in Q4.

LeMaitre Vascular, Inc. filed an amendment to its prior report to disclose its Board of Directors’ decision on how often shareholders will vote on executive pay. At the 2025 annual meeting, stockholders indicated a preference for holding the non-binding advisory Say-on-Pay vote every year.

After considering this stockholder vote, the Board determined that LeMaitre Vascular will conduct future Say-on-Pay votes on an annual basis. No other changes were made to the original report of the 2025 Annual Meeting voting results.

LeMaitre Vascular furnished a press release detailing its preliminary financial and operational results for the quarter ended September 30, 2025. The disclosure is provided under Item 2.02 and is not deemed “filed” for Section 18 purposes, nor incorporated by reference except as expressly set forth.

The report includes Exhibit 99.1 (press release) and Exhibit 104 (Inline XBRL cover page data) and contains a forward-looking statements disclaimer.

LeMaitre Vascular, Inc. (LMAT) insider transaction by Chairman and CEO George W. LeMaitre. The Form 4 reports transactions dated 09/05/2025 showing multiple non-derivative dispositions and one indirect acquisition into an irrevocable life insurance trust. Aggregate reported sales: 42,500 shares disposed (three entries: 10,600; 10,600; 21,300) at $0 reported price under code "G," and a separate entry showing 21,300 shares acquired indirectly into the "LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025." Following the reported sales, direct beneficial ownership counts are reduced to 1,663,303; 1,684,603; and 1,695,203 on respective lines, while the trust holds 21,300 shares indirectly. The filer disclaims beneficial ownership of the trust shares except to the extent of any pecuniary interest.